Dexter Yan is a senior writer covering China’s surging pharma industry on the APAC Pharma news team. With a keen interest in R&D and commercial activities taking place around the clock, he is always on the lookout for opportunities to keep readers better informed of any developments in the field.
Latest from Dexter Jie Yan
China has proposed new guidelines designed to head off potential bribery by pharma companies related to the conduct of clinical studies and possible manipulation of outcomes.
LaNova Medicines, as well as other Chinese RNA interference specialists and developers of stem cell-based therapies, were among those securing new funds from venture capital and private equity firms over the past few months.
The exact causes leading to Chinese authorities’ investigation of the UK major remain unclear at this point, but its key oncology drugs are facing fierce local competition from homegrown rivals.
ZL-1310, a DLL3-targeting ADC, has shown a 74% objective response rate in extensive-stage small cell lung cancer after platinum-based chemotherapy, making it a new contender in this setting.
Plus deal news involving LianBio/NImmune, REGiMMUNE/Kiji, Chengdu Baiyu/Novartis, Orasis/Optus, Takeda/Wave Life Sciences, Ono/LigaChem, Alchem/Sonnet, Astellas/AviadoBio, Innovent/Ask Pharm and Dr Reddy’s/Gilead.
Biostar plans to raise up to $41m through a Hong Kong IPO, which help the Chinese chemotherapy specialist progress lead asset utidelone for various oncology indications.